DE69835893T2 - Diagnostische tests und kits für clostridium difficile - Google Patents
Diagnostische tests und kits für clostridium difficile Download PDFInfo
- Publication number
- DE69835893T2 DE69835893T2 DE69835893T DE69835893T DE69835893T2 DE 69835893 T2 DE69835893 T2 DE 69835893T2 DE 69835893 T DE69835893 T DE 69835893T DE 69835893 T DE69835893 T DE 69835893T DE 69835893 T2 DE69835893 T2 DE 69835893T2
- Authority
- DE
- Germany
- Prior art keywords
- toxin
- difficile
- glutamate dehydrogenase
- assay
- clostridium difficile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract description 216
- 238000002405 diagnostic procedure Methods 0.000 title description 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims abstract description 242
- 101710182532 Toxin a Proteins 0.000 claims abstract description 242
- 238000003556 assay Methods 0.000 claims abstract description 143
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 claims abstract description 134
- 102000016901 Glutamate dehydrogenase Human genes 0.000 claims abstract description 131
- 238000009739 binding Methods 0.000 claims abstract description 119
- 230000027455 binding Effects 0.000 claims abstract description 118
- 238000000034 method Methods 0.000 claims abstract description 96
- 238000001514 detection method Methods 0.000 claims abstract description 85
- 231100000033 toxigenic Toxicity 0.000 claims abstract description 44
- 230000001551 toxigenic effect Effects 0.000 claims abstract description 44
- 101710182223 Toxin B Proteins 0.000 claims abstract description 31
- 239000007787 solid Substances 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 33
- 238000003018 immunoassay Methods 0.000 claims description 29
- 239000012530 fluid Substances 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 239000002250 absorbent Substances 0.000 claims description 9
- 230000002745 absorbent Effects 0.000 claims description 9
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 208000037384 Clostridium Infections Diseases 0.000 claims 1
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 1
- 238000003149 assay kit Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract description 84
- 239000011324 bead Substances 0.000 abstract description 45
- 239000000203 mixture Substances 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 17
- 239000012472 biological sample Substances 0.000 abstract description 11
- 239000012141 concentrate Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 73
- 239000000427 antigen Substances 0.000 description 47
- 108091007433 antigens Proteins 0.000 description 47
- 102000036639 antigens Human genes 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 36
- 239000012528 membrane Substances 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 230000035945 sensitivity Effects 0.000 description 32
- 229920001184 polypeptide Polymers 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000003321 amplification Effects 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000872 buffer Substances 0.000 description 20
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical class O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 229910000160 potassium phosphate Inorganic materials 0.000 description 18
- 235000011009 potassium phosphates Nutrition 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 239000005018 casein Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 15
- 235000021240 caseins Nutrition 0.000 description 15
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 238000001641 gel filtration chromatography Methods 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108700012359 toxins Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010020195 FLAG peptide Proteins 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 7
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 7
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 229940125717 barbiturate Drugs 0.000 description 6
- 239000013522 chelant Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 238000007885 magnetic separation Methods 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- -1 polypropylene Polymers 0.000 description 6
- 239000012898 sample dilution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003239 susceptibility assay Methods 0.000 description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 229920002704 polyhistidine Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 4
- CMNIWMBJUDZOQC-UHFFFAOYSA-N 2-methyl-3-oxobutanethioic s-acid Chemical compound CC(=O)C(C)C(S)=O CMNIWMBJUDZOQC-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101710112752 Cytotoxin Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 3
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
- WWVANQJRLPIHNS-BKPPORCPSA-N 2-iminobiotin Chemical compound N1C(=N)N[C@H]2[C@H](CCCCC(=O)O)SC[C@H]21 WWVANQJRLPIHNS-BKPPORCPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 150000001615 biotins Chemical class 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002444 silanisation Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AXTADRUCVAUCRS-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrole-2,5-dione Chemical compound OCCN1C(=O)C=CC1=O AXTADRUCVAUCRS-UHFFFAOYSA-N 0.000 description 1
- RMBMWXHVTXYPQN-UHFFFAOYSA-N 1-[3-[(1-hydroxy-2,5-dioxopyrrolidin-3-yl)methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1CC1=CC=CC(N2C(C=CC2=O)=O)=C1 RMBMWXHVTXYPQN-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US832935 | 1997-04-04 | ||
| US08/832,935 US5965375A (en) | 1997-04-04 | 1997-04-04 | Diagnostic tests and kits for Clostridium difficile |
| PCT/US1998/006702 WO1998045706A1 (en) | 1997-04-04 | 1998-04-03 | DIAGNOSTIC TESTS AND KITS FOR $i(CLOSTRIDIUM DIFFICILE) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69835893D1 DE69835893D1 (de) | 2006-10-26 |
| DE69835893T2 true DE69835893T2 (de) | 2007-03-08 |
Family
ID=25262976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69835893T Expired - Lifetime DE69835893T2 (de) | 1997-04-04 | 1998-04-03 | Diagnostische tests und kits für clostridium difficile |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5965375A (https=) |
| EP (1) | EP1019724B1 (https=) |
| JP (1) | JP2002510385A (https=) |
| AT (1) | ATE339688T1 (https=) |
| CA (1) | CA2285919C (https=) |
| DE (1) | DE69835893T2 (https=) |
| WO (1) | WO1998045706A1 (https=) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179611B2 (en) * | 1997-02-10 | 2007-02-20 | Bd Lee Laboratories | Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A |
| US5965375A (en) * | 1997-04-04 | 1999-10-12 | Biosite Diagnostics | Diagnostic tests and kits for Clostridium difficile |
| CA2344589A1 (en) * | 1998-09-21 | 2000-03-30 | Biosite Diagnostics | Diagnostic assays for detection of giardia lamblia |
| EP1141707A4 (en) * | 1998-12-29 | 2005-01-12 | Thermo Biostar Inc | METHODS FOR PRESENTING LIQUID AND SOLID COMPONENTS OF A SAMPLE FOR ANALYTICAL METHODS |
| RU2165622C2 (ru) * | 1999-02-11 | 2001-04-20 | Центр Государственного санитарно-эпидемиологического надзора в Красноярском крае | Способ регистрирования титра противодифтерийного антитоксина у взрослого населения крайнего севера |
| US7371584B2 (en) * | 1999-10-15 | 2008-05-13 | Wavesence, Inc. | Multi-functional and configurable assay |
| US6136549A (en) * | 1999-10-15 | 2000-10-24 | Feistel; Christopher C. | systems and methods for performing magnetic chromatography assays |
| US7390675B2 (en) * | 1999-10-15 | 2008-06-24 | Christopher Feistel | Multi-functional and configurable assay |
| CA2406707A1 (en) * | 2000-04-06 | 2001-10-18 | Robert Nagle | Microfluidic devices and systems incorporating cover layers |
| US20060029604A1 (en) * | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| US20060034828A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
| US20060257399A1 (en) * | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
| US20060024304A1 (en) * | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
| US20060034830A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
| JP2004511808A (ja) * | 2000-10-17 | 2004-04-15 | ベッスト−テスト アンパーツゼルスカブ | 体液サンプル中の生物学的細胞の直接的検出のためのアッセイ |
| WO2002062379A2 (en) * | 2001-02-09 | 2002-08-15 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabeth | Clostridium difficile vaccine |
| US6811549B2 (en) | 2001-02-16 | 2004-11-02 | William H. Fleming | Administration of therapeutic or diagnostic agents using interlabial pad |
| US20060034829A1 (en) * | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
| US20060024292A1 (en) * | 2001-12-27 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
| US7459127B2 (en) | 2002-02-26 | 2008-12-02 | Siemens Healthcare Diagnostics Inc. | Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces |
| US20030186463A1 (en) * | 2002-03-18 | 2003-10-02 | Robert Hudak | Method for clearing color and debris from or adding adjuvants or reactants to a selected portion of a chromatographic strip alone or in combination with a cell lysing step |
| GB0214947D0 (en) * | 2002-06-28 | 2002-08-07 | Secr Defence | Assay |
| US7094354B2 (en) | 2002-12-19 | 2006-08-22 | Bayer Healthcare Llc | Method and apparatus for separation of particles in a microfluidic device |
| US7125711B2 (en) | 2002-12-19 | 2006-10-24 | Bayer Healthcare Llc | Method and apparatus for splitting of specimens into multiple channels of a microfluidic device |
| AU2003293562A1 (en) * | 2002-12-26 | 2004-07-22 | Meso Scale Technologies, Llc | Methods, compositions and kits for biomarker extraction |
| US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
| US7435381B2 (en) | 2003-05-29 | 2008-10-14 | Siemens Healthcare Diagnostics Inc. | Packaging of microfluidic devices |
| CA2535153A1 (en) * | 2003-08-12 | 2005-05-19 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
| US7347617B2 (en) | 2003-08-19 | 2008-03-25 | Siemens Healthcare Diagnostics Inc. | Mixing in microfluidic devices |
| JP2007518062A (ja) * | 2003-09-29 | 2007-07-05 | バイオサイト インコーポレイテッド | 敗血症を診断する方法および診断するための組成物 |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| EP1773865A1 (en) * | 2004-08-03 | 2007-04-18 | Becton, Dickinson and Company | Use of magnetic material to fractionate samples |
| JP5308029B2 (ja) * | 2004-11-24 | 2013-10-09 | テクラブ インコーポレイテッド | 分析物を検出するための装置および方法 |
| US20080050832A1 (en) * | 2004-12-23 | 2008-02-28 | Buechler Kenneth F | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| CA2531616A1 (en) * | 2004-12-28 | 2006-06-28 | Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.) | High strength thin steel sheet having high hydrogen embrittlement resisting property and high workability |
| US7189522B2 (en) * | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| WO2006098804A2 (en) * | 2005-03-11 | 2006-09-21 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| EP2477029A1 (en) * | 2005-06-02 | 2012-07-18 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
| US20070020699A1 (en) * | 2005-07-19 | 2007-01-25 | Idexx Laboratories, Inc. | Lateral flow assay and device using magnetic particles |
| CA2615460A1 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| JP2009507482A (ja) * | 2005-09-09 | 2009-02-26 | グライコフィ， インコーポレイテッド | 主にｍａｎ７ｇｌｃｎａｃ２、ｍａｎ８ｇｌｃｎａｃ２グリコフォームを含むイムノグロブリン |
| WO2007041623A2 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US7655428B2 (en) * | 2005-12-22 | 2010-02-02 | Biosite, Inc. | Latent protein C assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| KR20090029184A (ko) * | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
| CA2679725C (en) * | 2007-02-28 | 2015-07-07 | Quantrx Biomedical Corporation | Folded perineal pad |
| US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US8268638B2 (en) * | 2007-07-18 | 2012-09-18 | Advantageous Systems, Llc | Methods and apparatuses for detecting analytes in biological fluid of an animal |
| WO2009108652A1 (en) | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| US20090263905A1 (en) | 2008-04-18 | 2009-10-22 | Kim Scheuringer | Detection test assembly for detecting the presence of a substance in a sample |
| EP2288719A4 (en) * | 2008-05-15 | 2012-01-11 | Univ Tufts | METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION |
| US20100022916A1 (en) | 2008-07-24 | 2010-01-28 | Javanbakhsh Esfandiari | Method and Apparatus for Collecting and Preparing Biological Samples for Testing |
| US20110287965A1 (en) * | 2008-11-26 | 2011-11-24 | Tzam Diagnostics Llc | Methods and compositions to detect clostridium difficile |
| CA2768528C (en) * | 2009-07-27 | 2017-05-23 | Christoph Von Eichel-Streiber | Method for detecting and identifying a variant c. difficile strain in a sample |
| US8765399B2 (en) | 2010-05-18 | 2014-07-01 | Montefiore Medical Center | Cultures and protocols for diagnosis of toxigenic Clostridium difficile |
| US9186668B1 (en) | 2010-06-04 | 2015-11-17 | Sandia Corporation | Microfluidic devices, systems, and methods for quantifying particles using centrifugal force |
| US9795961B1 (en) | 2010-07-08 | 2017-10-24 | National Technology & Engineering Solutions Of Sandia, Llc | Devices, systems, and methods for detecting nucleic acids using sedimentation |
| US8962346B2 (en) | 2010-07-08 | 2015-02-24 | Sandia Corporation | Devices, systems, and methods for conducting assays with improved sensitivity using sedimentation |
| US9304130B2 (en) | 2010-12-16 | 2016-04-05 | International Business Machines Corporation | Trenched sample assembly for detection of analytes with electromagnetic read-write heads |
| US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| US20120276060A1 (en) | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease |
| US10295535B2 (en) | 2011-04-29 | 2019-05-21 | Techlab, Inc. | Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease |
| WO2013043773A2 (en) | 2011-09-20 | 2013-03-28 | Avery Dennison Corporation | Embossed thermoplastic label |
| US9244065B1 (en) | 2012-03-16 | 2016-01-26 | Sandia Corporation | Systems, devices, and methods for agglutination assays using sedimentation |
| US9133527B2 (en) * | 2012-05-11 | 2015-09-15 | Techlab, Inc. | Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 |
| EP2852682B1 (en) | 2012-05-21 | 2017-10-04 | Fluidigm Corporation | Single-particle analysis of particle populations |
| ES2385625B2 (es) | 2012-05-29 | 2013-09-25 | Certest Biotec, S.L. | Dispositivo para el diagnóstico rápido de enfermedades causadas por Clostridium difficile en muestras fecales |
| KR101955329B1 (ko) * | 2012-06-08 | 2019-03-07 | 삼성전자주식회사 | 클로스트리디움 디피실리 균주 검출용 조성물과 키트 및 이를 이용한 검출 방법 |
| WO2013192620A1 (en) | 2012-06-22 | 2013-12-27 | Quantrx Biomedical Corporation | Method for obtaining fetal cells and fetal cellular components |
| US9903001B1 (en) | 2012-07-19 | 2018-02-27 | National Technology & Engineering Solutions Of Sandia, Llc | Quantitative detection of pathogens in centrifugal microfluidic disks |
| US9435800B2 (en) | 2012-09-14 | 2016-09-06 | International Business Machines Corporation | Sample assembly with an electromagnetic field to accelerate the bonding of target antigens and nanoparticles |
| US9304128B1 (en) * | 2013-02-01 | 2016-04-05 | Sandia Corporation | Toxin activity assays, devices, methods and systems therefor |
| US9500579B1 (en) | 2013-05-01 | 2016-11-22 | Sandia Corporation | System and method for detecting components of a mixture including tooth elements for alignment |
| US9803238B1 (en) | 2013-11-26 | 2017-10-31 | National Technology & Engineering Solutions Of Sandia, Llc | Method and apparatus for purifying nucleic acids and performing polymerase chain reaction assays using an immiscible fluid |
| FR3014446B1 (fr) * | 2013-12-10 | 2017-05-26 | Biomerieux Sa | Stabilisation de la gdh en solution aqueuse |
| DK3578635T3 (da) | 2014-04-02 | 2022-02-07 | Chembio Diagnostic Systems Inc | Immunoassay, som anvender indfangningskonjugat |
| DE102015220401B4 (de) | 2014-10-20 | 2022-12-29 | Gen-Probe Incorporated | Erythrozyten-Lyselösung |
| US20160116466A1 (en) | 2014-10-27 | 2016-04-28 | Chembio Diagnostic Systems, Inc. | Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses |
| US9702871B1 (en) | 2014-11-18 | 2017-07-11 | National Technology & Engineering Solutions Of Sandia, Llc | System and method for detecting components of a mixture including a valving scheme for competition assays |
| FI126289B (en) | 2014-12-19 | 2016-09-15 | Mobidiag Ltd | Method for detecting the presence of a hypervirulent strain of Clostridium difficile |
| US10254298B1 (en) | 2015-03-25 | 2019-04-09 | National Technology & Engineering Solutions Of Sandia, Llc | Detection of metabolites for controlled substances |
| JP6989927B2 (ja) | 2015-08-25 | 2022-02-03 | プロセナ バイオサイエンシーズ リミテッド | リン酸化アルファ－シヌクレインを検出するための方法 |
| CA3021914C (en) | 2016-04-27 | 2024-04-30 | Gen-Probe Incorporated | Blood cell lysis reagent |
| US10981174B1 (en) | 2016-08-04 | 2021-04-20 | National Technology & Engineering Solutions Of Sandia, Llc | Protein and nucleic acid detection for microfluidic devices |
| US10406528B1 (en) | 2016-08-04 | 2019-09-10 | National Technology & Engineering Solutions Of Sandia, Llc | Non-contact temperature control system for microfluidic devices |
| US10786811B1 (en) | 2016-10-24 | 2020-09-29 | National Technology & Engineering Solutions Of Sandia, Llc | Detection of active and latent infections with microfluidic devices and systems thereof |
| EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
| EP3765031A4 (en) | 2018-03-14 | 2022-03-23 | Memorial Sloan Kettering Cancer Center | ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF |
| EP3938400B1 (en) | 2019-03-11 | 2025-07-30 | Memorial Sloan Kettering Cancer Center | Cd22 antibodies and methods of using the same |
| US11597961B2 (en) | 2019-04-22 | 2023-03-07 | Qualitic Biotechnology LLC | Rapid colorimetric diagnostic test for C. difficile |
| CA3140406A1 (en) | 2019-05-28 | 2020-12-03 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
| CN112661849B (zh) * | 2020-12-17 | 2022-05-20 | 杭州贤至生物科技有限公司 | 一种艰难梭菌重组蛋白单克隆抗体的制备方法和应用 |
| CN117700560B (zh) * | 2023-12-08 | 2024-05-31 | 北京新兴四寰生物技术有限公司 | 抗艰难梭菌谷氨酸脱氢酶的单克隆抗体及其应用 |
| CN119751687B (zh) * | 2024-12-26 | 2025-09-26 | 杭州医学院 | 识别艰难梭菌谷氨酸脱氢酶中线性b细胞抗原表位的驼源单域抗体ga4及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937201A (en) * | 1982-06-10 | 1990-06-26 | Mitsubishi Kasei Corporation | Latex reagent for detection of the toxin of clostridium difficile |
| US4530833A (en) * | 1982-09-13 | 1985-07-23 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4533630A (en) * | 1982-09-13 | 1985-08-06 | Wilkins Tracy D | Toxins and antibodies of C. difficile |
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US4628037A (en) * | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
| US4695392A (en) * | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4672040A (en) * | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
| US4554088A (en) * | 1983-05-12 | 1985-11-19 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4695393A (en) * | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4863852A (en) * | 1985-07-03 | 1989-09-05 | Virginia Tech Intellectual Properties, Inc. | Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors |
| US5071759A (en) * | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US5231003A (en) * | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| JP3290988B2 (ja) * | 1991-04-11 | 2002-06-10 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | 多重リガンドを同時検出する新規接合体及び検定法 |
| US5610023A (en) * | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| US5965375A (en) * | 1997-04-04 | 1999-10-12 | Biosite Diagnostics | Diagnostic tests and kits for Clostridium difficile |
-
1997
- 1997-04-04 US US08/832,935 patent/US5965375A/en not_active Expired - Lifetime
-
1998
- 1998-04-03 EP EP98918009A patent/EP1019724B1/en not_active Expired - Lifetime
- 1998-04-03 AT AT98918009T patent/ATE339688T1/de not_active IP Right Cessation
- 1998-04-03 WO PCT/US1998/006702 patent/WO1998045706A1/en not_active Ceased
- 1998-04-03 JP JP54295998A patent/JP2002510385A/ja active Pending
- 1998-04-03 CA CA002285919A patent/CA2285919C/en not_active Expired - Lifetime
- 1998-04-03 DE DE69835893T patent/DE69835893T2/de not_active Expired - Lifetime
-
1999
- 1999-07-29 US US09/363,960 patent/US6503722B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2285919A1 (en) | 1998-10-15 |
| EP1019724B1 (en) | 2006-09-13 |
| EP1019724A1 (en) | 2000-07-19 |
| JP2002510385A (ja) | 2002-04-02 |
| EP1019724A4 (en) | 2004-10-06 |
| US5965375A (en) | 1999-10-12 |
| WO1998045706A1 (en) | 1998-10-15 |
| US6503722B1 (en) | 2003-01-07 |
| DE69835893D1 (de) | 2006-10-26 |
| CA2285919C (en) | 2009-06-02 |
| ATE339688T1 (de) | 2006-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69835893T2 (de) | Diagnostische tests und kits für clostridium difficile | |
| DE3486262T2 (de) | Verfahren zur Herstellung eines monoklonalen Antikörpers mit Spezifizität für vernetzte Fibrinderivate und ein Testverfahren mittels dieses Antikörpers. | |
| DE2522086C2 (de) | Reagenz zum Abtrennen und Bestimmen von in biologischen Fluiden vorhandenen AK:Ag-Komplexen | |
| DE69637136T2 (de) | Screening von kombinatorischen Peptidbibliotheken zur Selektion von Peptidliganden zur Verwendung in der Affinitätsreinigung von Zielproteinen | |
| EP1972938B1 (de) | Teststreifen für die Bestimmung des Kariesrisikos | |
| EP0944832B1 (de) | ANTIGENSPEZIFISCHER IgM-NACHWEIS | |
| DE19649390A1 (de) | Antigenspezifischer IgG-Nachweis | |
| EP0407904B1 (de) | Verfahren zur Bestimmung eines Analyten | |
| DE4040669A1 (de) | Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik | |
| DE3942999C2 (de) | Verfahren zum Nachweis von malignen Erkrankungen | |
| EP1061369A2 (de) | Element, Verfahren und Kit zur Bestimmung eines Analyts in einer Flüssigkeit | |
| DE68920251T2 (de) | Bestimmung eines chlamydialen oder gonokokkalen Antigens unter Verwendung eines positiv geladenen ionischen Bindungsträgers. | |
| DE3650497T2 (de) | Verfahren und Zusammensetzung zum Nachweis von Analyt-Anteilen | |
| DE60033183T2 (de) | Transplantatabstossung und damit verbundene zustände | |
| DE69331580T2 (de) | Nachweis von beweglichen zellen in einer probe | |
| DE69022889T2 (de) | Diagnostischer Testsatz und Verfahren zum Nachweis des Chlamydia-Antigens unter Verwendung einer Membran mit Hydroxylgruppen an der Oberfläche. | |
| EP0547059B1 (de) | Pankreas-elastase-1-spezifischer antikörper, ein verfahren zu seiner gewinnung und ein testkit der solche antikörper enthält | |
| DE68919982T2 (de) | Ein Sulfydril enthaltendes Reduktionsmittel enthaltende stabilisierte Extraktionszusammensetzung und deren Verwendung zur Bestimmung von Chlamydia und Gonokokken. | |
| DE69529787T2 (de) | Testsatz und Methode für eine Bestimmung durch kompetitive spezifische Bindung | |
| EP0554458B1 (en) | Immunoassay and monoclonal antibody for determining diarrheal shellfish poisons | |
| DE102009021681B4 (de) | Verwendung von Staphylococcus aureus bindenden Peptiden, Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Staphylococcus aureus, Staphylococcus aureus bindendes Peptid und dafür kodierende Nukleinsäure | |
| DE3650635T2 (de) | Monoklonale Antikörper | |
| DE102005031755B9 (de) | Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp. | |
| DE4314998A1 (de) | Monoklonale Antikörper gegen filamentöse Phagen, ihre Herstellung und Verwendung zum Nachweis und zur Isolierung der Phagen | |
| DE3781181T2 (de) | Reagenz mit monoklonalantikoerpern zu bakteroides gingivalis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |